Summary
Even with vaccines and treatments, the virus that causes COVID-19 remains a persistent global health threat. To stay ahead of the disease, scientists are constantly searching for new ways to disrupt the virus. One promising target is a vital viral enzyme called papain-like protease, or PLpro. The virus uses this enzyme to process its own building blocks and to suppress the human immune system. If researchers can disable PLpro, they can effectively stop the virus from multiplying and hiding.
In a recent study, researchers set out to find new chemical inhibitors that could block this critical enzyme. By screening a vast library of chemicals and designing new ones based on existing drug structures, they discovered several promising candidates. One specific molecule, known as compound 2t, emerged as the clear standout. Computer models showed that compound 2t fits snugly into the active center of the viral enzyme, forming a highly stable blockade.
When put to the test in laboratory dishes, compound 2t successfully shut down the PLpro enzyme and demonstrated strong antiviral activity. Crucially, the researchers found that the chemical was able to attack the virus without causing any toxic damage to the surrounding healthy human cells.
Why it matters.
As the virus continues to mutate, it threatens to outsmart our current medical defenses. Most antiviral drugs on the market target entirely different viral machinery. Developing a drug that targets the PLpro enzyme would give doctors a brand new weapon to fight COVID-19, which could be especially useful for vulnerable patient populations or against drug-resistant viral strains. A future drug based on this research could be prescribed alongside existing treatments to deliver a powerful, multi-targeted strike against the infection.
However, it will be a while before this compound reaches patients. The research is currently in its earliest stages, with findings limited to computer modeling and biochemical tests in laboratory dishes. Compound 2t will need to undergo rigorous testing in animal models and human clinical trials to ensure it is both safe and effective in living bodies. Nonetheless, uncovering a strong chemical candidate is the crucial first step toward a new generation of COVID-19 medicines.
The story in numbers.
- IC50 of non-covalent inhibitor 2t (TPG-2t)
- 0.634 µM
- EC50 antiviral activity for inhibitor 2t
- 2.89 µM
- IC50 of covalent inhibitor 13f (TPG-13f)
- 5.0 µM
Follow the evidence.
This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.